VEGFA and pulmonary arterial hypertension: These results suggest that VEGF inhibition during Atez/Bev therapy might have a negative effect PAH, and early diagnosis of PAH is important to determine whether Atez/Bev needs to be discontinued or a specific treatment for PAH needs to be added.